Stockholm Fashion District Hosts Fashion Week Trade Where Swedish Initiatives Are Paving the Way for a Bright New Future
Stockholm Fashion District is revolutionizing the fashion industry by offering a vibrant platform for designers, creatives and buyers to connect. Unlike traditional trade platforms that occur just twice a year, Stockholm Fashion District hosts multiple trade shows annually - pushing the boundaries of industry conventions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240813925340/en/
Catwalk on the Grand Opening of Fashion Week Trade, 12-16 August 2024 (Photo: Business Wire)
This innovative approach allows creatives in the industry to connect, inspire and gain valuable market exposure, all under the same roof.
"The fashion industry is ever changing, therefore initiatives in trade conventions are crucial to reflect the current landscape and its eager pioneers" says Helena Walker, CEO Stockholm Fashion District
During this Fashion Week Trade, 12-16 August, Stockholm Fashion District opens its doors to one of the biggest trade events of the year. By incorporating 700 fashion brands, ranging from mid-market to premium, the event seamlessly blends different brands showcasing fashion, shoes and accessories.
With its purpose of bringing people together, the event will celebrate creativity and innovation by having fashion enthusiasts and professionals attending from all around the world. Relationships and businesses will grow.
"The world around us is definitely very challenging for our industry. Cooperation, flexibility, and transition are the way to the future, and we are a reliable player and meeting place for the industry. Together we create energy to find new opportunities." says Helena Walker, CEO Stockholm Fashion District
The fashion industry in Sweden is a significant contributor to the country's economy, generating a revenue of 173 billion SEK and employing around 40,000 people. Sweden is known for its emphasis on innovation, entrepreneurship, sustainability, and creativity - values that are reflected in the fashion industry.
Beyond the conventional twice-a-year fashion trade convention, Stockholm Fashion District is providing a year-round platform for designers, creatives and buyers to connect. Linking Swedish fashion enterprises to the global market, the area hosts 22 yearly sales-focused events in addition to its 143 showrooms that are open year-round. Along with collaborative opportunities and training sessions, Trade Partners Sweden supports with legal, logistical, and sales expertise. The organization supports fashion professionals all year round.
Fashion Week Trade is taking place between 12–16 August in Stockholm
Link to the program here
Link to the brand list here
For more information about the Swedish fashion industry, read the Fashion Transformation Report here.
ABOUT:
Stockholm Fashion District (SFD)
https://www.stockholmfash iondistrict.se
Trade Partners Sweden (TPS)
https://www.tradepartnerssweden.se/
Trade Partners Sweden is a member organization representing Swedish agents, suppliers, and distributors in fashion, shoes, and textiles. They are the founders of Stockholm Fashion District, a company that serves as the physical meeting place for the industry in Sweden and hosts events including Fashion Week Trade.
PRESS IMAGES:
Click here
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813925340/en/
Contacts
PRESS CONTACT:
Linda Ekstrom, Head of Marketing & Communications
linda.ekstrom@tradepartners.se, - linda.ekstrom@tradepartners.se +46 73 525 99
53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom